00:00In P.J.M. in a situation, there is a lymphoma, which is a cancer.
00:06The cancer is in which way, which can be found in which way, which can be found in which way,
00:12which can be found in which way.
00:17Dr. Gaurav Prakash is here with Dr. Gaurav.
00:24Dr. Gaurav Prakash.
00:28Dr. Gaurav Prakash, you will know that this whole thing is going to be done in September.
00:39Dr. Gaurav Prakash is a cancer.
00:44Dr. Gaurav Prakash, which is the lymphoma cancer?
00:49Dr. Gaurav Prakash is a cancer center of the lung cancer.
00:57Dr. Gaurav Frakash is the maker for symptoms of a cancer.
00:58We all get are people from access to the gang, which is called lymph node.
01:03Dr. Gaurav Prakash's function enters the lung vector.
01:10Dr. Gaurav Prakash's plankton system becomes the immune cell of the哪裡 called lympho-sides.
01:29We call lymphoma lymphoma lymphocytes.
01:44We call lymphoma lymphocytes.
02:22We call lymphoma lymphocytes.
02:30We call lymphoma lymphocytes.
03:28We call lymphoma lymphocytes.
03:29We call lymphoma lymphocytes.
03:58And we call lymphoma lymphoma lymphocytes.
04:27sequencing, next generation sequencing, and we have studied many genes.
04:33Our main finding of this research is that there is a gene that is notch1.
04:40Notch1 is a gene that we see in Western countries,
04:43where there are most genetic researches, such as America, Europe,
04:47there is a gene that is 1-2% of the disease,
04:50while in our data, it is 10.4%,
04:54it is 10% of the disease in this gene.
04:57Another gene is the P53 gene,
05:00and we call it the guardian of the genome,
05:03because when this gene is mutated,
05:06it makes the disease very quickly,
05:08and the effects of the disease in this gene is less.
05:10We also found that in our patient group,
05:14the Tp53 gene, which was the probability,
05:19was more than the average population,
05:21and this is the case of the gene.
05:24If we talk about these diseases,
05:27we have 2 parts of the research.
05:30One of them,
05:31one of them, who has not taken care of the disease,
05:33and one of them,
05:38one of them,
05:52for the gene.
05:53We have seen this is an observational research,
05:56which we have seen that,
05:57in Indian lymphoma patients
05:59which are disturbed genes,
06:02and what is the mutation of the disease and treatment
06:06on the treatment of them.
06:08The main finding we had found,
06:10that EZB subtype
06:12of lymphoma,
06:13which is a genetic subtype,
06:15which is survival has better.
06:16We have seen this in our research.
06:18and which patients have TP53 mutation, their survival is poor.
06:24Now this research is the start of the research,
06:27which we know is that which genes in India,
06:30can change or change in different ways.
06:34The next part of this research is that
06:36what we can use these patients to benefit from these patients.
06:42You will understand that the research is a long process.
06:46We have done the first CDE,
06:50which is a very meaningful result.
06:52At the time of this research,
06:55we will see the different genetic changes
06:59that we have received from these patients.
07:00We can improve the disease and improve the disease.
07:07These are the PGI's hematology and oncology department.
07:14Dr. Gaurav Prakash,
07:16who has told us that this research,
07:19which has been done,
07:19this is a long period of time.
07:21This will also be further.
07:23You will know that this lymphoma cancer,
07:27which is causing the disease,
07:29which is causing the age group,
07:31which is causing the disease,
07:33which is causing the disease.
07:34This is the camera person,
07:36which is causing the disease.
07:37This is the number of people,
07:38which is causing the disease.
07:38This is the number of people,
07:38which is causing the disease.
07:39This has been a bit more entirety.
07:39This has made us a prophesying plant environment.
07:39This can be聴AMA,
